Clinical Trials Logo

Clinical Trial Summary

This is a Phase 1a/1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SG301 in Patients with Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies


Clinical Trial Description

After a screening period of up to 28 days for each study phase, qualified patients will be enrolled to receive their assigned dose of SG301, administered weekly for the first 2 cycles and every 2 weeks thereafter, until disease progression or intolerable toxicity, starting of a new anticancer treatment, withdrawal of consent, lost to follow up, death, or end of the study, whichever occurs first. The study consists of a dose escalation phase (Phase 1a) and a dose expansion phase (Phase 1b) in subjects with relapsed or refractory multiple myeloma and other hematological malignancies. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04684108
Study type Interventional
Source Hangzhou Sumgen Biotech Co., Ltd.
Contact
Status Active, not recruiting
Phase Phase 1
Start date November 4, 2021
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT04932967 - Use of nMoABs for the Treatment of COVID-19 in Patients With HM.
Not yet recruiting NCT02900768 - Effects of Exercise on Allogeneic Stem Cell Transplant N/A
Recruiting NCT04082910 - Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells Phase 1/Phase 2
Recruiting NCT05510089 - Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies N/A
Terminated NCT04093622 - Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
Recruiting NCT06106360 - A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
Recruiting NCT06225856 - An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies Phase 1
Recruiting NCT02828462 - Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics
Completed NCT01714180 - Effect of Body Mass on Acyclovir Pharmacokinetics N/A
Completed NCT03241550 - A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients Phase 1
Completed NCT02598752 - Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation
Completed NCT02880709 - The Effect of Special Diets in Hematological Cancer Patients Phase 4
Completed NCT00894049 - A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation Phase 2
Completed NCT04687982 - Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002). N/A
Completed NCT00897260 - Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders N/A
Recruiting NCT03850366 - HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib Phase 2
Not yet recruiting NCT06066255 - PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM Phase 2
Enrolling by invitation NCT05364359 - Individual Dietary Counseling Based on Taste-tests in Patients With Hematological Cancer in Cytostatic Therapy N/A
Recruiting NCT04841447 - Membrane Target Detection for Leukemia Treatment
Not yet recruiting NCT06279585 - Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD N/A